The DELC study suggested that high baseline serum IL-6 levels at the time of enzalutamide administration may lead to a poor prognosis and that IL-6 in the serum may cause the progression of prostate cancer independently of AR. This evidence concerns the gene IL6 and prostate carcinoma.